SCHEMBL9909095

SCHEMBL9909095

CC1=C(C#N)[C@@H](C)C(C#N)=C(c2ccccc2Cl)N1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 12/20 0.44
MAPT P10636 11/20 0.44
HPGD P15428 6/20 0.44
SMN1; SMN2 Q16637 2/20 0.44
KDM4E B2RXH2 9/20 0.39
NPSR1 Q6W5P4 3/20 0.39
HIF1A Q16665 2/20 0.39
KMT2A Q03164 3/20 0.39
HTT P42858 2/20 0.39
NPC1 O15118 1/20 0.39
CYP1A2 P05177 1/20 0.39
CYP2C9 P11712 1/20 0.39
CYP2C19 P33261 1/20 0.39
GAA P10253 4/20 0.37
LMNA P02545 3/20 0.37
POLB P06746 2/20 0.37
RECQL P46063 1/20 0.37
TDP1 Q9NUW8 1/20 0.37
MET P08581 1/20 0.35
DRD5 P21918 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9906913 0.84 MAPT (0.39) ALDH1A1MAPTHPGDSMN1; SMN2KDM4E
SCHEMBL9909073 0.80 MAPT (0.46) ALDH1A1MAPTHPGDSMN1; SMN2KDM4E
SCHEMBL14155609 0.80 MAPT (0.46) ALDH1A1MAPTHPGDSMN1; SMN2KDM4E
SCHEMBL4996298 0.78 ALDH1A1 (0.49) ALDH1A1MAPTHPGDSMN1; SMN2KDM4E
SCHEMBL9909092 0.77 MET (0.53) ALDH1A1MAPTHPGDSMN1; SMN2KDM4E
SCHEMBL9909108 0.77 MAPT (0.44) ALDH1A1MAPTHPGDSMN1; SMN2KDM4E
SCHEMBL9909098 0.72 KDM4E (0.46) ALDH1A1MAPTHPGDSMN1; SMN2KDM4E
SCHEMBL14155675 0.72 ALDH1A1 (0.40) ALDH1A1MAPTHPGDSMN1; SMN2KDM4E
SCHEMBL14155635 0.71 MET (0.42) ALDH1A1MAPTHPGDSMN1; SMN2KDM4E
SCHEMBL9909107 0.71 MET (0.42) ALDH1A1MAPTHPGDSMN1; SMN2KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8198456-B2 e.g. 1,4-dihydro-4-(1H-indazol-5-yl)-2,6-dimethyl-3,5-pyridinedicarbonitrile; c-Met tyrosine kinase inhibitor; antitumor agent; lung, liver, gastric and breast solid tumors; pancreatic cancer, glioma, and hepatocellular carcinoma BAYER INTELLECTUAL PROPERTY GMBH (DE) 2012-06-12 US disclosed
US-20080176833-A1 DIHYDROPYRIDINE DERIVATIVES AS USEFUL AS PROTEIN KINASE INHIBITORS BAYER INTELLECTUAL PROPERTY GMBH (DE) 2008-07-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080176833-A1 DIHYDROPYRIDINE DERIVATIVES AS USEFUL AS PROTEIN KINASE INHIBITORS MET, DMPK, RET ALDH1A1 1341/4885MAPT 1550/4885HPGD 2338/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.